Science Explorer Interactive view Map
Company · Bromma · Sweden

Moberg Pharma (Sweden)

mobergpharma.comROR OpenAlex
Research works
4
▼ 22% vs 2013–17
Citations
66
14.7 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
48%
world 28%

Not ranked overall: Moberg Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which research topics does Moberg Pharma (Sweden) publish most on?

By volume in 2022–2025: Clostridium difficile and Clostridium perfringens research, Antibiotic Use and Resistance, Nosocomial Infections in ICU and Nail Diseases and Treatments.

Clostridium difficile and Clostridium perfringens research: 0 fractional worksAntibiotic Use and Resistance: 0 fractional worksNosocomial Infections in ICU: 0 fractional worksNail Diseases and Treatments: 0 fractional worksFungal Infections and Studies: 0 fractional worksPlant Pathogens and Fungal Diseases: 0 fractional works
Infectious DiseasesApplied Microbiology and BiotechnologyCritical Care and Intensive Care MedicineEpidemiology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Clostridium difficile and Clostridium perfringens research Infectious Diseases 0 works
  2. 2 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 0 works
  3. 3 Nosocomial Infections in ICU Critical Care and Intensive Care Medicine 0 works
  4. 4 Nail Diseases and Treatments Epidemiology 0 works
  5. 5 Fungal Infections and Studies Epidemiology 0 works
  6. 6 Plant Pathogens and Fungal Diseases Cell Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available48.3%not open51.7%

World: 28% of research is openly available.

with international co-authors57.3%domestic only42.7%

World: 19% is written across borders.

How has Moberg Pharma (Sweden)'s research output changed?

Output in 2018–2022 was 22% lower than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Bromma

All research institutions in Bromma

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.